Trulicity (Dulaglutide) for Type 2 Diabetes

How Dulaglutide Works in Type 2 Diabetes

Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing a modified GLP-1 analogue to an immunoglobulin Fc fragment, extending its half-life to approximately 5 days. This allows once-weekly dosing. The drug mimics endogenous GLP-1, a gut-derived incretin hormone that rises after meals.

In type 2 diabetes, the incretin effect is blunted. Endogenous GLP-1 secretion may be preserved, but the insulinotropic response to it diminishes as beta-cell function declines 1. Dulaglutide restores glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing glucagon release from alpha cells. Because this mechanism is glucose-dependent, hypoglycemia risk remains low when dulaglutide is used without sulfonylureas or insulin.

Beyond glycemic control, dulaglutide slows gastric emptying (which blunts postprandial glucose spikes) and acts on hypothalamic appetite centers to reduce caloric intake. The FDA approved dulaglutide in September 2014 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes 2. In 2020, the label expanded to include reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Clinical Trial Evidence: The AWARD and REWIND Programs

The efficacy of dulaglutide for type 2 diabetes rests on two major trial programs. The AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) series established glycemic efficacy, while REWIND demonstrated cardiovascular protection.

AWARD trials. Across six phase III AWARD trials enrolling over 5,000 patients, dulaglutide 1.5 mg reduced HbA1c by 0.8% to 1.6% from baseline, depending on comparator and background therapy. In AWARD-1 (N=978), dulaglutide 1.5 mg reduced A1c by 1.51% versus 0.99% for exenatide twice daily at 26 weeks 3. In AWARD-3, dulaglutide 1.5 mg outperformed metformin monotherapy with a 1.1% A1c reduction at 52 weeks.

REWIND trial. The landmark REWIND study (N=9,901) randomized adults with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors to dulaglutide 1.5 mg or placebo, with a median follow-up of 5.4 years 4. The primary composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death occurred in 12% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88 to 95% CI 0.79, 0.99, P=0.026). This 12% relative risk reduction was consistent across subgroups, including patients without prior cardiovascular events.

What made REWIND distinct from other GLP-1 receptor agonist cardiovascular outcomes trials: 69% of participants had no prior cardiovascular disease at enrollment. This broadened the evidence for cardiovascular protection to a primary prevention population, not only secondary prevention.

The American Diabetes Association (ADA) 2024 Standards of Care cite GLP-1 receptor agonists with proven cardiovascular benefit (including dulaglutide) as preferred second-line agents after metformin in patients with established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk 5.

Dosing Protocol for Type 2 Diabetes

Dulaglutide is available in four dose strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Each is delivered via a single-use prefilled autoinjector pen. The dosing schedule is straightforward.

Initiation. Start at 0.75 mg subcutaneously once weekly. This dose can be used as monotherapy or combined with other glucose-lowering agents. Inject on the same day each week, at any time of day, with or without food. If a dose is missed, administer it within 3 days of the missed dose; if more than 3 days have passed, skip to the next scheduled dose.

Titration. After at least 4 weeks at 0.75 mg, increase to 1.5 mg weekly if additional glycemic control is needed. The label permits further escalation to 3.0 mg after at least 4 weeks at 1.5 mg, and then to the maximum 4.5 mg after at least 4 weeks at 3.0 mg 2.

Higher doses. The 3.0 mg and 4.5 mg doses were studied in AWARD-11 (N=1,842), where dulaglutide 4.5 mg reduced A1c by 1.87% from a baseline of 8.6%, compared to 1.54% with 1.5 mg at 36 weeks 6. Weight loss was also greater: 4.7 kg with 4.5 mg versus 3.1 kg with 1.5 mg.

Injection sites. Abdomen, thigh, or upper arm. Rotate sites each week. The pen's hidden needle design means patients never see or handle the needle, which reduces injection anxiety and improves adherence.

HbA1c Reduction: What to Expect

Most patients see measurable A1c lowering within 2 to 4 weeks. The plateau effect occurs around 12 to 16 weeks. Speed of response depends on baseline A1c: patients starting above 9.0% typically experience larger absolute reductions.

Across the AWARD trials, the 1.5 mg dose reliably brought A1c down by 1.0% to 1.6%. The 4.5 mg dose in AWARD-11 provided an additional 0.3% reduction beyond the 1.5 mg dose. For context, the ADA defines adequate response as reaching an individualized A1c target (typically <7.0% for most adults) within 3 to 6 months of starting or adjusting therapy.

A pooled analysis of 7,596 participants across AWARD trials found that 55% to 66% of patients on dulaglutide 1.5 mg achieved A1c <7.0%, compared to 30% to 48% on comparators including sitagliptin, insulin glargine, and metformin 7.

Dr. Hertzel Gerstein, principal investigator of REWIND, noted: "Dulaglutide produced sustained glycemic improvements over 5 years of follow-up while simultaneously reducing cardiovascular events, which changes how we think about treating type 2 diabetes early in its course" 4.

Cardiovascular and Renal Benefits Beyond Glucose

The cardiovascular protection dulaglutide provides is not simply a downstream effect of better glucose control. REWIND showed MACE reduction despite modest between-group A1c differences (approximately 0.6% separation at month 12 that narrowed over time). Multiple mechanisms likely contribute: reduced systemic inflammation, improved endothelial function, lower blood pressure (2 to 4 mmHg systolic reduction), and modest lipid improvements.

REWIND also demonstrated renal benefits. The composite renal outcome (new macroalbuminuria, sustained 30% decline in eGFR, or renal replacement therapy) occurred in 17.1% of the dulaglutide group versus 19.6% of placebo (HR 0.85 to 95% CI 0.77, 0.93) 8. This renal benefit was driven primarily by reduction in new macroalbuminuria, which is clinically meaningful for the roughly 40% of type 2 diabetes patients who develop some degree of diabetic kidney disease.

The Endocrine Society and ADA both recommend GLP-1 receptor agonists with cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, independent of A1c level or metformin use 5.

Side Effects in Type 2 Diabetes Patients

Gastrointestinal effects are the most common adverse reactions. They typically emerge during the first 2 weeks of a new dose and diminish over 4 to 8 weeks.

Common (occurring in >5% of patients):

• Nausea (12% to 21% across doses)
• Diarrhea (8% to 12%)
• Vomiting (6% to 12%)
• Abdominal pain (6% to 9%)
• Decreased appetite (5% to 8%)

Less common but clinically relevant:

• Injection site reactions (0.5% to 1.5%)
• Fatigue (4%)
• Tachycardia (increase of 2 to 4 beats per minute on average)

Serious but rare:

• Pancreatitis (reported in <0.5% of clinical trial participants). Discontinue if pancreatitis is suspected.
• Thyroid C-cell tumors: dulaglutide carries a boxed warning based on rodent studies showing thyroid C-cell tumors with GLP-1 receptor agonists. Relevance to humans is unknown. The drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome 2.

Hypoglycemia incidence is low (<2%) when dulaglutide is used without insulin or sulfonylureas. When combined with insulin or sulfonylureas, providers should consider reducing the dose of those agents to mitigate hypoglycemia risk.

Weight Effects in Type 2 Diabetes

Dulaglutide produces moderate weight loss. In AWARD-1, mean weight change at 52 weeks was -1.3 kg with 0.75 mg and -2.3 kg with 1.5 mg 3. AWARD-11 showed greater weight loss at higher doses: -3.1 kg with 1.5 mg, -4.0 kg with 3.0 mg, and -4.7 kg with 4.5 mg at 36 weeks 6.

This weight reduction is meaningful but less than what semaglutide 2.4 mg produces (approximately 15% body weight in STEP-1). For patients whose primary goal is substantial weight loss, semaglutide may be preferred. For patients whose primary goals are A1c control and cardiovascular protection with a once-weekly injectable, dulaglutide's efficacy-to-tolerability ratio is competitive.

How Dulaglutide Compares to Other GLP-1 Receptor Agonists

The GLP-1 receptor agonist class now includes semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro), and exenatide (Byetta, Bydureon). How does dulaglutide fit?

Versus semaglutide (Ozempic). The SUSTAIN-7 trial did not directly compare dulaglutide and semaglutide in a head-to-head with the newer dulaglutide doses. However, indirect comparisons suggest semaglutide 1.0 mg produces slightly greater A1c reduction (approximately 0.2% to 0.4% more) and greater weight loss than dulaglutide 1.5 mg 9. The 4.5 mg dulaglutide dose narrows this gap. Both drugs reduce MACE; SUSTAIN-6 showed a 26% reduction for semaglutide (though with fewer participants and shorter follow-up than REWIND).

Versus tirzepatide (Mounjaro). Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces larger A1c reductions (up to 2.3% in SURPASS trials) and more weight loss than any single-incretin GLP-1 receptor agonist. For patients needing maximal glycemic and weight-loss efficacy, tirzepatide may be preferred. Dulaglutide retains an advantage in long-term cardiovascular outcome data and longer post-marketing safety history.

Practical considerations. Dulaglutide's prefilled pen requires no reconstitution, no dose dialing, and no needle attachment. The device simplicity may improve adherence for patients who find injectable therapy intimidating.

Who Should and Should Not Use Dulaglutide

Appropriate candidates:

• Adults with type 2 diabetes needing A1c reduction beyond what metformin alone achieves
• Patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors (strongest evidence for benefit)
• Patients who prefer once-weekly injection over daily or twice-daily dosing
• Adults with type 2 diabetes and chronic kidney disease stages 1 to 3 (dose adjustment not required)

Contraindications and cautions:

• Personal or family history of medullary thyroid carcinoma or MEN2
• History of pancreatitis (relative caution; not an absolute contraindication per label, but risk-benefit should be discussed)
• Severe gastrointestinal disease (gastroparesis may worsen)
• Type 1 diabetes (dulaglutide is not indicated)
• Pregnancy (discontinue at least 2 months before planned conception due to the long washout period)

The 2024 ADA Standards of Care recommend considering GLP-1 receptor agonists with proven cardiovascular benefit as first injectable therapy before basal insulin in most patients with type 2 diabetes, unless insulin is specifically indicated by hyperglycemic emergency or very high A1c (>10%) with symptoms 5.

Insurance Coverage and Cost Considerations

Trulicity's wholesale acquisition cost is approximately $950 to $1,050 per month (four weekly pens) without insurance. Most commercial plans and Medicare Part D formularies cover Trulicity, though tier placement and prior authorization requirements vary.

Coverage typically requires documentation of: a confirmed type 2 diabetes diagnosis (A1c ≥6.5% or equivalent), inadequate control on metformin (or documented intolerance), and sometimes trial-and-failure of a preferred formulary GLP-1 receptor agonist. Eli Lilly offers a savings card program that can reduce out-of-pocket cost to $25 per fill for commercially insured patients.

For Medicare Part D enrollees, the Inflation Reduction Act cap of $2,000 annual out-of-pocket spending (effective 2025) means even high-cost drugs like Trulicity become more accessible once that threshold is reached.